SUPPORT LINE

0300 111 1234

Message

EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

NICE will appraise Tolvaptan

User Rating: 3 / 5

Star ActiveStar ActiveStar ActiveStar InactiveStar Inactive
 

The Department of Health has asked NICE - the National Institute for Health and Care Excellence - to conduct an appraisal of tolvaptan for treating ADPKD (autosomal dominant polycystic kidney disease). The date of the appraisal meeting will be 1st April 2015.

The PKD Charity has been invited to make a submission to NICE about patient and carer experience of living with ADPKD. The submission will also include information from people who have been on the tolvaptan drug trials in the UK. 

If tolvaptan receives 'marketing authorisation' from the EMA and the outcome of the appraisal is positive, NICE will recommend the use of tolvaptan within the NHS.

Print Email

0
0
0
s2sdefault

Latest Tweets

PKD Charity is a Member of

  • Fundraising Regulator Website
  • Visit The Information Standard website
  • Visit PKD International website
  • Visit Ciliopathy Alliance website
  • Visit the Genetic Alliance UK website
  • Rare Disease UK Website
  • National Voices Website
  • Specialised Healthcare Alliance Website
  • FEDERG Website
  • Visit EURORDIS website